Holger Rosenbrock

Q: What is Holger Rosenbrock email address?

Email Holger Rosenbrock at holger.rosenbrock@gmx.de and holger.rosenbrock@boehringer-ingelheim.com. This email is the most updated Holger Rosenbrock email found in 2026.

Q: How to contact Holger Rosenbrock?

To contact Holger Rosenbrock send an email to holger.rosenbrock@gmx.de or holger.rosenbrock@boehringer-ingelheim.com.

Distinguished Research Fellow - Head of Late Phase CNS Diseases Research at Boehringer Ingelheim | Ulm, Baden-Württemberg, Germany

About Holger Rosenbrock

Holger Rosenbrock serves as a Distinguished Research Fellow and Head of Late Phase CNS Diseases Research at Boehringer Ingelheim, where he leverages over 20 years of extensive experience in preclinical research focused on central nervous system (CNS) diseases. His expertise spans a wide array of CNS indications, including Alzheimer's disease, schizophrenia, and depression, making him a pivotal figure in the drug discovery process. Holger's role involves leading a dedicated team of Research Project Leaders, guiding cross-functional drug discovery projects from target identification and validation to the qualification of clinical candidates.

Under his leadership, the department is committed to advancing the precision psychiatry concept, ensuring that drug discovery efforts are tailored to the unique biological and clinical profiles of CNS disorders. Holger is responsible for managing the late-phase research project portfolio, which includes overseeing the pharmacology aspects of clinical development projects. His deep understanding of psychopharmacology, synaptic plasticity, and signal transduction enables him to drive innovative approaches in translational research, ultimately enhancing the efficacy and safety of therapeutic candidates.

Holger's collaborative spirit and strategic vision foster an environment where scientific inquiry thrives, allowing his team to tackle the complexities of CNS diseases with cutting-edge methodologies. His commitment to advancing the field is evident in his ongoing efforts to bridge the gap between preclinical findings and clinical applications, ensuring that Boehringer Ingelheim remains at the forefront of CNS drug development.

Holger Rosenbrock Work